Literature DB >> 25068425

Angioedema in patients treated with sirolimus and ACE inhibitor post hematopoietic SCT.

M Jung1, V N Ranpura2, C E Dunbar1, J F Tisdale3, C D Fitzhugh3, M M Hsieh3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25068425      PMCID： PMC4221485          DOI： 10.1038/bmt.2014.162

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients.

Authors:  Giovanni Stallone; Barbara Infante; Salvatore Di Paolo; Antonio Schena; Giuseppe Grandaliano; Loreto Gesualdo; Francesco Paolo Schena
Journal:  Nephrol Dial Transplant       Date:  2004-11       Impact factor: 5.992

2.  A role for mammalian target of rapamycin in regulating T cell activation versus anergy.

Authors:  Yan Zheng; Samuel L Collins; Michael A Lutz; Amy N Allen; Thomas P Kole; Paul E Zarek; Jonathan D Powell
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

3.  Incidence and characteristics of angioedema associated with enalapril.

Authors:  John B Kostis; Harold J Kim; James Rusnak; Thomas Casale; Allen Kaplan; Jonathan Corren; Elliott Levy
Journal:  Arch Intern Med       Date:  2005-07-25

4.  Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.

Authors:  Guillaume Pare; Michiaki Kubo; James B Byrd; Catherine A McCarty; Alencia Woodard-Grice; Koon K Teo; Sonia S Anand; Rebecca L Zuvich; Yuki Bradford; Stephanie Ross; Yusuke Nakamura; Marylyn Ritchie; Nancy J Brown
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

Review 5.  Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells.

Authors:  Adam T Waickman; Jonathan D Powell
Journal:  J Immunol       Date:  2012-05-15       Impact factor: 5.422

6.  Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme.

Authors:  R J Falk; J Scheinman; G Phillips; E Orringer; A Johnson; J C Jennette
Journal:  N Engl J Med       Date:  1992-04-02       Impact factor: 91.245

7.  Early detection and the course of glomerular injury in patients with sickle cell anemia.

Authors:  A Guasch; M Cua; W E Mitch
Journal:  Kidney Int       Date:  1996-03       Impact factor: 10.612

8.  Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients.

Authors:  Michael Duerr; Petra Glander; Fritz Diekmann; Duska Dragun; Hans-H Neumayer; Klemens Budde
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 8.237

9.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.

Authors:  N J Brown; W A Ray; M Snowden; M R Griffin
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

10.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245
  10 in total
  3 in total

Review 1.  The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.

Authors:  Beje Thomas; Matthew R Weir
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

2.  ACE inhibitor-associated intestinal angioedema in orthotopic heart transplantation.

Authors:  Dushyanth Srinivasan; Garth W Strohbehn; Thomas Cascino
Journal:  ESC Heart Fail       Date:  2017-03-23

3.  Sirolimus-induced severe small bowel angioedema: A case report.

Authors:  Hui Yang; Wei Wang; Xiaopeng Hu; Xiaodong Zhang; Lihong Liu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.